Allworth Financial LP Invests $5.96 Million in Gilead Sciences, Inc. $GILD

Key Points

• Allworth Financial purchased 47,192 Gilead Sciences shares worth approximately $5.96 million, while institutional investors and hedge funds collectively own 83.67% of the company.
• Gilead reported quarterly revenue of $7.80 billion, up 10.6% year over year, and exceeded analysts’ EPS expectations. The company also declared a quarterly dividend of $0.82 per share, representing an annualized yield of about 2.3%.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $158.04, although some firms have lowered targets and company insiders sold shares under pre-arranged trading plans.

Allworth Financial LP bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 47,192 shares of the biopharmaceutical company's stock, valued at approximately $5,962,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Gilead Sciences in the 2nd quarter valued at $15,393,785,000. Vanguard Group Inc. grew its stake in Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock valued at $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. State Street Corp lifted its stake in Gilead Sciences by 1.9% in the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock worth $7,393,921,000 after purchasing an additional 1,151,213 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Gilead Sciences by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company's stock worth $3,399,734,000 after purchasing an additional 1,195,269 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock valued at $2,837,948,000 after purchasing an additional 3,046,688 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 2.8%

GILD opened at $143.44 on Friday. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The business has a 50 day moving average price of $131.56 and a two-hundred day moving average price of $136.52. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market cap of $177.86 billion, a PE ratio of -53.72 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.01 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.51 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the transaction, the chief financial officer directly owned 165,646 shares in the company, valued at approximately $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 82,000 shares of company stock worth $10,837,860. 0.30% of the stock is owned by corporate insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s collaboration with Nucleai highlights a potential strategic shift toward data-driven oncology. Nucleai’s spatial-biology and artificial-intelligence capabilities could help Gilead identify biomarkers, improve patient selection and support its cancer-drug pipeline, although the financial impact remains uncertain. Does Gilead Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
• Positive Sentiment: BMO Capital reaffirmed its Buy rating, reinforcing the view that Gilead’s HIV franchise, oncology investments and pipeline can support further gains. BMO Capital Reaffirms Buy Rating on Gilead Sciences
• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast from a loss of $1.05 to a loss of $0.65 and increased its FY2027 estimate from $9.11 to $9.30. Several quarterly estimates for late 2026 and 2027 were also raised, suggesting improving expectations for future profitability.
• Neutral Sentiment: The recent rally extended to seven consecutive sessions, indicating strong momentum, but the subsequent consolidation may reflect profit-taking as the stock trades near its 52-week high. Gilead Rises for the Seventh Straight Session
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82, equivalent to $3.28 annually and a yield of roughly 2.3%. The payout supports income-oriented investors, though the reported negative payout ratio reflects currently distorted earnings.
• Negative Sentiment: Zacks lowered its FY2028 EPS forecast from $10.00 to $9.58 and cut estimates for Q1 and Q2 2028. Although several nearer-term estimates increased, the mixed revisions signal uncertainty around the longer-term earnings trajectory.
• Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares for approximately $415,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan and left him with substantial holdings, making it a limited bearish signal, but insider selling can weigh modestly on sentiment. Gilead Sciences CFO Sells 3,000 Shares

Analysts Set New Price Targets

GILD has been the subject of a number of analyst reports. Daiwa Securities Group dropped their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a report on Tuesday, May 19th. Weiss Ratings downgraded Gilead Sciences from a "buy (b-)" rating to a "hold (c-)" rating in a research report on Tuesday, August 11th. Maxim Group raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price target on the stock in a research note on Wednesday, May 20th. Leerink Partners lowered shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $155.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Twenty-four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $158.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source